Healthcare [ 10/13 ] | Biotechnology [ 87/159 ]
NASDAQ | Common Stock
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.
It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV.
Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 23 | -0.4 Decreased by -300% | -0.48 Increased by +16.67% |
| Aug 8, 23 | -0.34 Increased by +10.53% | -0.47 Increased by +27.66% |
| May 8, 23 | -0.43 Increased by +15.69% | -0.48 Increased by +10.42% |
| Feb 28, 23 | -0.41 Decreased by -130.6% | -0.45 Increased by +8.89% |
| Nov 7, 22 | -0.1 Increased by +70.59% | -0.44 Increased by +77.27% |
| Aug 8, 22 | -0.38 Decreased by -2 K% | -0.52 Increased by +26.92% |
| May 10, 22 | -0.51 Decreased by -250% | -0.58 Increased by +12.07% |
| Feb 28, 22 | 1.34 Increased by +39.58% | 0.17 Increased by +688.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -33.14 M Decreased by -310.89% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -28.18 M Increased by +10.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -35.47 M Increased by +15.51% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by -100% | -34.43 M Decreased by -129.4% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by -100% | -8.07 M Increased by +71.39% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by -100% | -31.34 M Decreased by -2.14 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by -100% | -41.98 M Decreased by -236.68% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 192.18 M Increased by +295.16% | 117.13 M Increased by +467.06% | Increased by +60.95% Increased by +43.5% |